HLA B*5701 status, disease progression, and response to antiretroviral therapy

AIDS

Volumn 27, Issue 16, 2013, Pages 2587-2592

  Jose, Miss Sophie ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiretroviral therapy progression; HIV; HLA B 5701

Indexed keywords

ABACAVIR; HLA B ANTIGEN; ANTIRETROVIRUS AGENT; HLA-B*57:01 ANTIGEN; HLA B*57:01 ANTIGEN;

ADULT; ARTICLE; ASSOCIATION; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HAZARD RATIO; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; VIRUS LOAD; GENETICS; HIV INFECTIONS; IMMUNOLOGY; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; UNITED KINGDOM; METHODOLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HLA-B ANTIGENS; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84885432525     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/01.aids.0000432613.95455.71     Document Type: Article

References (16)

1. M5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-732.
2. Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004; 5:203-211.
3. M5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568-579.
4. M5701 as a marker for immunologically confirmed abacavir hyper-sensitivity in white and black patients. Clin Infect Dis 2008; 46:1111-1118.
5. M5701 screening and abacavir hypersensitivity: a single centre experience. AIDS 2007; 21:2533-2534.
6. Salgado M, Simon A, Sanz-Minguela B, Rallon NI, Lopez M, Vicario JL, et al. An additive effect of protective host genetic factors correlates with HIV nonprogression status. J Acquir Immune Defic Syndr 2011; 56:300-305.
7. Gao X, O'Brien TR, Welzel TM, Marti D, Qi Y, Goedert JJ, et al. HLA-B alleles associate consistently with HIV heterosexual transmission, viral load, and progression to AIDS, but not susceptibility to infection. AIDS 2010; 24:1835-1840.
8. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317: 944-947.
9. M5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 2000; 97:2709-2714.
10. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Ann Rev Med 2003; 54:535-551.
11. M57. AIDS 2002; 16: 961-972.
12. Yu XG, Lichterfeld M, Chetty S, Williams KL, Mui SK, Miura T, et al. Mutually exclusive T-cell receptor induction and differential susceptibility to human immunodeficiency virus type 1 mutational escape associated with a two-amino-acid difference between HLA class I subtypes. J Virol 2007; 81:1619-1631.
13. Ahuja SK, Kulkarni H, Catano G, Agan BK, Camargo JF, He W, et al. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med 2008; 14:413-420.
14. Kuniholm MH, Gao X, Xue X, Kovacs A, Anastos K, Marti D, et al. Human leukocyte antigen genotype and risk of HIV disease progression before and after initiation of antiretroviral therapy. J Virol 2011; 85:10826-10833.
15. UK Collaborative HIV Cohort Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004; 5:115-124.
16. Brumme ZL, Brumme CJ, Chui C, Mo T, Wynhoven B, Woods CK, et al. Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy. J Infect Dis 2007; 195:1694-1704.